Jun 2026 (Q2 FY26) — Jul 30, 2026
Tempus AI Q2 FY26 — Strong Revenue Growth, FDA Approval, and Strategic Acquisition
Read the full callTempus AI (TEM) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Tempus AI earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 382 | +21.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -19.9 | −0.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 5.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
7 of 8 judged targets kept · 12 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| AstraZeneca/Pathos foundation model, first version delivery | first version completed in about 9 to 12 months | Mar 2025 | We introduced initial results from and successfully delivered the first version of our foundation model to AstraZeneca. | Achieved |
| ASP uplift from xT CDx / xF regulatory initiatives | about $500 upside, playing out over the course of 2026 | Dec 2025 | We expect an estimated $200 uplift in ASP, which equates to approximately $85 million on an annual basis beginning in 2027. | Delayed |
| Full-year adjusted EBITDA guidance | approximately $65 million | Dec 2025 | We expect 2026 adjusted EBITDA to be approximately $65 million, an improvement of about $72 million over 2025 | On Track |
1 of Tempus AI, Inc.'s 20 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.
Claimed
- Total revenues increased 22% to $382.5 million.
- Data and apps revenues grew 28% year-over-year to $93.2 million, with data licensing and modeling insights up 36%.
- Received FDA approval for tumor-only xT CDx, expected to uplift ASP by $200, equating to approximately $85 million annually starting 2027.
- Signed large multiyear data licensing and modeling agreements with BioNTech, Daiichi Sankyo, LevelSet Bio, and Insight Pharmaceuticals, contributing to approximately $200 million in total bookings.
- Completed a $460 million convertible senior notes offering, saving over $30 million annually in interest expense and enabling positive free cash flow by year-end.
- Adjusted EBITDA improved by $13.6 million year-over-year to $8 million.
- Acquired Personalis to accelerate MRD testing commercial adoption, a $20 billion+ market.
- Increased full-year 2026 revenue guidance to $1.595 billion-$1.605 billion (25% growth) and adjusted EBITDA guidance to $65 million ($72 million improvement over 2025).
Qualified
- Slower growth in hereditary cancer testing, up 5% to $107.4 million, due to lapping an abnormally high growth period in Q2 2025.
Price
$64.34 −0.59% · −$0.38
Performance −26.7% 1Y
1Y: $87.78 on 17 Oct 2025 → $64.34. High $92.45 (20 Oct 2025), low $41.55 (29 Jul 2026).
- Previous close
- $64.72
- 52-week range
- $41.55 – $92.45
- One year
- −30.41%
Overview
- Symbol
- TEM
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
7 of 8 judged targets kept · 12 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| AstraZeneca/Pathos foundation model, first version delivery | first version completed in about 9 to 12 months | Mar 2025 | We introduced initial results from and successfully delivered the first version of our foundation model to AstraZeneca. | Achieved |
| ASP uplift from xT CDx / xF regulatory initiatives | about $500 upside, playing out over the course of 2026 | Dec 2025 | We expect an estimated $200 uplift in ASP, which equates to approximately $85 million on an annual basis beginning in 2027. | Delayed |
| Full-year adjusted EBITDA guidance | approximately $65 million | Dec 2025 | We expect 2026 adjusted EBITDA to be approximately $65 million, an improvement of about $72 million over 2025 | On Track |
Claimed
- Total revenues increased 22% to $382.5 million.
- Data and apps revenues grew 28% year-over-year to $93.2 million, with data licensing and modeling insights up 36%.
- Received FDA approval for tumor-only xT CDx, expected to uplift ASP by $200, equating to approximately $85 million annually starting 2027.
- Signed large multiyear data licensing and modeling agreements with BioNTech, Daiichi Sankyo, LevelSet Bio, and Insight Pharmaceuticals, contributing to approximately $200 million in total bookings.
- Completed a $460 million convertible senior notes offering, saving over $30 million annually in interest expense and enabling positive free cash flow by year-end.
- Adjusted EBITDA improved by $13.6 million year-over-year to $8 million.
- Acquired Personalis to accelerate MRD testing commercial adoption, a $20 billion+ market.
- Increased full-year 2026 revenue guidance to $1.595 billion-$1.605 billion (25% growth) and adjusted EBITDA guidance to $65 million ($72 million improvement over 2025).
Qualified
- Slower growth in hereditary cancer testing, up 5% to $107.4 million, due to lapping an abnormally high growth period in Q2 2025.
The full ledger
Open Tempus AI, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 20 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Tempus AI Q1 FY26 — Strong Revenue Growth and Increased Full-Year Guidance
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Tempus AI Q4 FY25 — Strong Growth in Diagnostics and Data, Driven by AI Advantage
Read the full callEvery analysed call
Tempus AI earnings calls (TEM)
Financials
What the filings say
Net profit, year on year: +113% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 181 | 201 | 256 | 315 | 334 | 367 | 348 | 382 |
| Expenses | 235 | 251 | 324 | 376 | 395 | 429 | 433 | 458 |
| Operating profit | -54 | -51 | -69 | -62 | -61 | -61 | -85 | -76 |
| Operating margin | −29.6% | −25.3% | −26.9% | −19.6% | −18.3% | −16.7% | −24.3% | −19.9% |
| Profit before tax | -74 | -10 | -112 | -41 | -81 | -57 | -123 | 9 |
| Tax rate | −0.1% | −1.2% | 41.1% | −0.5% | −0.3% | 10.5% | 0.1% | 3.5% |
| Net profit | -76 | -13 | -68 | -43 | -80 | -54 | -126 | 6 |
| EPS ($ per share) | -0.46 | — | -0.40 | -0.25 | -0.46 | — | -0.70 | 0.03 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Reserves | — | -1,397 | -2,151 | -2,396 |
| Total liabilities | — | 841 | 870 | 1,784 |
| Fixed assets | — | 62 | 58 | 89 |
| Total assets | — | 564 | 926 | 2,275 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -168 | -214 | -189 | -218 |
| Cash from investing | -58 | -40 | -130 | -398 |
| Cash from financing | 251 | 118 | 494 | 884 |
| Net cash flow | 25 | -137 | 175 | 268 |
| Capital expenditure | -18 | -35 | -22 | -21 |
| Free cash flow | -187 | -249 | -211 | -239 |
TEM revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | — | — | — | — | — | — | 75% | 76% | — |
| Clinical Order | 61% | 58% | 71% | 70% | 70% | 67% | 69% | 69% | +19.3% |
| Data and Applications | — | — | — | — | — | — | 25% | 24% | — |
| Insights Product | 25% | 28% | 19% | 18% | 21% | 22% | 20% | 20% | +35.8% |
| Genomics Product | 68% | 64% | 76% | 77% | 76% | -168% | 6% | 7% | -89.7% |
| Trials Product | 6% | 6% | 4% | 3% | 3% | 3% | 3% | 2% | -8.2% |
| Next Product | — | — | — | — | — | — | 2% | 2% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
TEM operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Average selling price (ASP) Diagnostics | ~$1,640And then in response to the ASP question, so ASPs in Q4 were around $1,640.Source: earnings call transcript | ~$1,740I do -- we do believe that ASPs are likely to rise years by virtue back that our current ASP sits at around 1740 or something like that, somewhere in that range, 720.Source: earnings call transcript | — | — |
| Procedures MRD | 4,700We were simply highlighting the really unbelievable strength of our MRD offering on -- the main vector being we ran 4,700 tests.Source: earnings call transcript | 6,500I mean our MRD assay grew 500%, but it was only 6,500 a test.Source: earnings call transcript | ~9,000Even with that, we are delivering growth rates that have exceeded our expectations, running approximately 6,500 tests in Q1 and approximately 9,000 tests in Q2, growing 38% quarter-over-quarter.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
259 filings between Oct 28, 2025 and Sep 25, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$220.89M
233 sales by 11 insiders
91% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Award — granted as compensation
Also filed: 6 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| LEFKOFSKY ERIC P | — | $190.85M | Sep 22, 2026 |
| Fukushima Ryan | — | $12.60M | Sep 16, 2026 |
| Rogers James William | — | $6.92M | Aug 19, 2026 |
| Polovin Andrew | — | $5.03M | Sep 17, 2026 |
| Schoenherr Thomas Edward | — | $2.06M | Sep 25, 2026 |
| Bartolucci Ryan M | — | $1.31M | Sep 17, 2026 |
| Phelps Erik | — | $881.8K | Feb 19, 2026 |
| Doudna Jennifer A | — | $455.2K | Sep 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Schoenherr Thomas Edward CEO, Diagnostics | Sale 10b5-1 plan | 10,281 | $873.9K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 432 | $34.1K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 184 | $14.5K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 24 | $1.9K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 79,259 | $6.13M |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 4,420 | $341.6K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 17,359 | $1.33M |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 2,091 | $163.6K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 965 | $73.9K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 160 | $12.6K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 33,770 | $2.61M |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 29,367 | $2.27M |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 7,394 | $566.2K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 6,431 | $492.4K |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 37,950 | $2.97M |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 14,042 | $1.10M |
| Sep 22, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 16,152 | $1.26M |
| Sep 17, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 645 | $52.3K |
| Sep 17, 2026 | Bartolucci Ryan M Chief Accounting Officer | Sale 10b5-1 plan | 7,062 | $529.6K |
| Sep 17, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 6,855 | $552.0K |
| Sep 17, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 11,609 | $941.4K |
| Sep 17, 2026 | Polovin Andrew EVP, Chief Legal Officer | Sale 10b5-1 plan | 2,951 | $221.3K |
| Sep 17, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 4,942 | $400.7K |
| Sep 17, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 52,558 | $4.23M |
| Sep 17, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 123,391 | $9.94M |
| Sep 16, 2026 | Fukushima Ryan CEO, Data | Sale 10b5-1 plan | 700 | $49.0K |
| Sep 1, 2026 | Fukushima Ryan CEO, Data | Sale 10b5-1 plan | 1,000 | $64.6K |
| Sep 1, 2026 | Fukushima Ryan CEO, Data | Sale 10b5-1 plan | 10,900 | $682.8K |
| Sep 1, 2026 | Fukushima Ryan CEO, Data | Sale 10b5-1 plan | 13,046 | $810.4K |
| Sep 1, 2026 | Fukushima Ryan CEO, Data | Sale 10b5-1 plan | 5,900 | $376.4K |
| Sep 1, 2026 | Epstein David R Director | Sale 10b5-1 plan | 250 | $16.4K |
| Sep 1, 2026 | Doudna Jennifer A Director | Sale 10b5-1 plan | 676 | $44.3K |
| Aug 28, 2026 | West Nadja Director | Sale 10b5-1 plan | 3,000 | $207.0K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 578 | $38.7K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 2,887 | $199.1K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 1,668 | $116.5K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 1,365 | $93.0K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 102 | $7.2K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 3,649 | $244.5K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 8,926 | $608.1K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 4,218 | $282.6K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 10,282 | $700.5K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 19,605 | $1.35M |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 22,495 | $1.55M |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 12,851 | $897.4K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 660 | $42.3K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 760 | $48.7K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 782 | $55.2K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 3,944 | $260.2K |
| Aug 25, 2026 | LEFKOFSKY ERIC P CEO and Chairman | Sale 10b5-1 plan | 1,883 | $121.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Tempus AI, Inc.
Free account. Everything above stays public.
Write why you follow Tempus AI, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading